Եվրոպական Միություն - շվեդերեն - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiska medel - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Շվեդիա - շվեդերեն - Läkemedelsverket (Medical Products Agency)

g.l. pharma gmbh - tapentadoltartrat - depottablett - 100 mg - tapentadoltartrat 167,81 mg aktiv substans

Շվեդիա - շվեդերեն - Läkemedelsverket (Medical Products Agency)

g.l. pharma gmbh - tapentadoltartrat - depottablett - 25 mg - tapentadoltartrat 41,953 mg aktiv substans

Շվեդիա - շվեդերեն - Läkemedelsverket (Medical Products Agency)

g.l. pharma gmbh - tapentadoltartrat - depottablett - 200 mg - tapentadoltartrat 335,62 mg aktiv substans

Շվեդիա - շվեդերեն - Läkemedelsverket (Medical Products Agency)

g.l. pharma gmbh - tapentadoltartrat - depottablett - 50 mg - tapentadoltartrat 83,905 mg aktiv substans

Շվեդիա - շվեդերեն - Läkemedelsverket (Medical Products Agency)

g.l. pharma gmbh - tapentadoltartrat - depottablett - 150 mg - tapentadoltartrat 251,715 mg aktiv substans

Շվեդիա - շվեդերեն - Läkemedelsverket (Medical Products Agency)

g.l. pharma gmbh - tapentadoltartrat - depottablett - 250 mg - tapentadoltartrat 419,525 mg aktiv substans

Շվեդիա - շվեդերեն - Läkemedelsverket (Medical Products Agency)

sun pharmaceutical industries europe b.v. - esomeprazolnatrium - pulver till injektions-/infusionsvätska, lösning - 40 mg - esomeprazolnatrium 42,5 mg aktiv substans

Շվեդիա - շվեդերեն - Läkemedelsverket (Medical Products Agency)

uni-pharma kleon tsetis pharmaceutical laboratories s.a. - tiamazol - tablett - 5 mg - tiamazol 5 mg aktiv substans; laktosmonohydrat hjälpämne

Շվեդիա - շվեդերեն - Läkemedelsverket (Medical Products Agency)

rph pharmaceuticals ab - glibenklamid - tablett - 1,75 mg - glibenklamid 1,75 mg aktiv substans; laktosmonohydrat hjälpämne - glibenklamid